Checkpoint Therapeutics Inc. (CKPT), a clinical-stage immunotherapy and targeted oncology company, is making a second attempt to get FDA approval for its lead drug candidate Cosibelimab.
Cosibelimab, an anti-programmed death ligand-1 ("PD-L1") antibody, is being developed for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com